{
  "pmcid": "5833621",
  "sha256": "e3ff92d0b2118ae70c1bf19c06ee582ecd31156335463f9b260a12cace28c7a2",
  "timestamp_utc": "2025-11-09T23:59:25.875571+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 12.62937209302326,
    "reading_ease": 27.492662790697693,
    "word_count": 258
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Adjuvant Radiotherapy Plus Chemotherapy vs Chemotherapy Alone in Locally Advanced Bladder Cancer"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Conducted as a randomised phase 2 trial at an academic center"
      },
      "Participants": {
        "score": 2,
        "evidence": "Eligibility criteria included age ≤70 years, ≥pT3b, grade 3, or positive nodes, and negative margins post-RC"
      },
      "Intervention": {
        "score": 2,
        "evidence": "Interventions were chemotherapy plus RT (2 cycles of gemcitabine and cisplatin before and after RT) versus chemotherapy alone (4 cycles of gemcitabine and cisplatin)"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study investigates whether adjuvant radiotherapy (RT) plus chemotherapy enhances locoregional recurrence-free survival (LRFS) compared to chemotherapy alone"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was LRFS over 2 years"
      },
      "Randomisation_Allocation": {
        "score": 1,
        "evidence": "Randomisation was weighted to expedite accrual"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "A total of 120 patients were randomised: 75 to chemotherapy plus RT and 45 to chemotherapy alone"
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "analysed using an intention-to-treat approach"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "LRFS was 96% vs 69% (HR, 0.08; 95% CI, 0.02-0.39; P < .01)"
      },
      "Harms": {
        "score": 1,
        "evidence": "RT-associated late grade 3 gastrointestinal adverse effects were observed in 7% of the chemotherapy plus RT group"
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCT01734798"
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified"
      }
    },
    "total_score": 19,
    "max_score": 25
  }
}